Tagged with Strategy

Pharma Marc Alexander Burmeister of B. Braun France speaks about the country’s role as a production hub for B. Braun’s global operations, its 2020 strategy to reach USD 200 million in investments, and the French affiliate’s growth through acquisition of SMEs. The B. Braun Group recently shared its Strategy 2020 in…

Pharma Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not only achieve their growth ambitions but also provide better services to its clients. You were appointed CEO of Recipharm Italy…

Italy The president of Chiesi explains how innovation and a strong focus on quality have led to outstanding growth and have established the Italian family-run business as a significant pharma player around the world. He furthermore elaborates on Chiesi’s strategy to maintain growth abroad and reviews the challenge of attracting and…

Pharma Jean-Paul Berthomé, the CEO of Laboratoires Expanscience, talks about the company’s global ambitions, flagship products and strategies to tackle challenges in emerging economies. With a presence in highly saturated markets, proper positioning has been at the heart of their branding success. Laboratoires Expanscience has over 60 years’ history, with well-known…

Pharma Alexander Zehnder discusses Sanofi’s sizable contribution to the Italian economy, manufacturing in Italy, and the country’s labyrinthine drug approval processes. What have been your main areas of focus and priorities since your appointment as head of Sanofi’s Italy and Malta operations in October 2014? Sanofi is in the midst of a transition from…

Pharma LEO Pharma is expanding its global presence and continuing its leading role in the number of skin disease patients treated and in thrombosis care. Head of the company’s French affiliate, the largest globally, Mr. Guillaume Clement shares his perspective on the company’s new initiatives in efforts to meet ambitious future…

Pharma Anne-Marie Noir discusses footcare, Laboratoires Asepta’s corporate values, the strategic development behind their innovative brand, and the company’s positioning in Monaco. She also discusses her family’s legacy in the business and her influence as a powerful woman in a male-dominated industry. Laboratories Asepta has been a very successful company in…

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your speech today, you mentioned that the concept of patient-centrality has not changed, but that expectations around it have; could you…

Pharma Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry and for patients. What is the main focus of your work at Nanobiotix, a company you co-founded 12 years ago,…

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…

Pharma Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has with France, general manager Jerome Bouyer offers an optimistic view of how the French healthcare sector can best be structured…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…